Skip to main content
Journal cover image

Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study.

Publication ,  Journal Article
Safdar, N; Smith, J; Knasinski, V; Sherkow, C; Herrforth, C; Knechtle, S; Andes, D
Published in: Diagn Microbiol Infect Dis
January 2010

We undertook a retrospective cohort study comparing infection in solid organ transplant recipients receiving alemtuzumab (n = 726) versus basiliximab (n = 215) or antithymocyte globulin (ATG) (n = 85). Eighty-one percent of patients had kidney transplants. Overall, 33% of patients in the alemtuzumab group (240/724) developed infection compared with 40% (87/215) in the basiliximab group (odds ratio [OR], 0.72; 95% confidence interval [CI], 0.53-0.99; P = .04). The frequency of infection was similar in the alemtuzumab and ATG groups (33% versus 36%, respectively, P = .53). The frequency of fungal infections, most caused by Candida spp., was similar in the alemtuzumab and basiliximab groups (10% versus 9%); disseminated fungal infection occurred in 68% of the patients with fungal infection receiving alemtuzumab and in 30% of the patients with fungal infection receiving basiliximab (OR, 4.76; 95% CI, 1.58-14.28; P = .003). Basiliximab posed a higher risk than alemtuzumab for infection. Disseminated candidal infections were more common in patients receiving alemtuzumab.

Duke Scholars

Published In

Diagn Microbiol Infect Dis

DOI

EISSN

1879-0070

Publication Date

January 2010

Volume

66

Issue

1

Start / End Page

7 / 15

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Recombinant Fusion Proteins
  • Opportunistic Infections
  • Mycoses
  • Middle Aged
  • Microbiology
  • Male
  • Kidney Transplantation
  • Immunosuppressive Agents
  • Immunoglobulin G
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Safdar, N., Smith, J., Knasinski, V., Sherkow, C., Herrforth, C., Knechtle, S., & Andes, D. (2010). Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn Microbiol Infect Dis, 66(1), 7–15. https://doi.org/10.1016/j.diagmicrobio.2009.08.017
Safdar, Nasia, Jeannina Smith, Valerie Knasinski, Colleen Sherkow, Casey Herrforth, Stuart Knechtle, and David Andes. “Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study.Diagn Microbiol Infect Dis 66, no. 1 (January 2010): 7–15. https://doi.org/10.1016/j.diagmicrobio.2009.08.017.
Safdar N, Smith J, Knasinski V, Sherkow C, Herrforth C, Knechtle S, et al. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn Microbiol Infect Dis. 2010 Jan;66(1):7–15.
Safdar, Nasia, et al. “Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study.Diagn Microbiol Infect Dis, vol. 66, no. 1, Jan. 2010, pp. 7–15. Pubmed, doi:10.1016/j.diagmicrobio.2009.08.017.
Safdar N, Smith J, Knasinski V, Sherkow C, Herrforth C, Knechtle S, Andes D. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn Microbiol Infect Dis. 2010 Jan;66(1):7–15.
Journal cover image

Published In

Diagn Microbiol Infect Dis

DOI

EISSN

1879-0070

Publication Date

January 2010

Volume

66

Issue

1

Start / End Page

7 / 15

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Recombinant Fusion Proteins
  • Opportunistic Infections
  • Mycoses
  • Middle Aged
  • Microbiology
  • Male
  • Kidney Transplantation
  • Immunosuppressive Agents
  • Immunoglobulin G